CatalystFDA/Bio

Ivonescimab Monotherapy Demonstrates Statistically Significant Overall Survival Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in HARMONi-2 Study Conducted by Akeso in

Statistically significant OS benefit over pembrolizumab in PD-L1+ NSCLC from HARMONi-2 trial.

What changed

Statistically significant OS benefit over pembrolizumab in PD-L1+ NSCLC from HARMONi-2 trial.

Why it matters

Statistically significant OS benefit over pembrolizumab in PD-L1+ NSCLC from HARMONi-2 trial. — impact context not separately stored; see What changed.

Sources

eodhd